Ocuphire Pharma Inc

About Ocuphire Pharma Inc

Ocuphire Pharma (NASDAQ: OCUP) focuses on developing and commercializing therapies for eye disorders. Specializing in innovative ophthalmic solutions, Ocuphire addresses significant unmet medical needs in conditions like night vision disturbances and presbyopia. Key projects include its lead candidate, Nyxol, an eye drop formulation targeting multiple indications. The company's objectives revolve around advancing Nyxol through clinical trials and gaining regulatory approvals to bring these therapies to the market. Ocuphire is driven by a commitment to improving the quality of life for patients with vision problems through groundbreaking research and collaboration with healthcare professionals.

What is Ocuphire Pharma Inc known for?

Snapshot

2018

Year founded

Employees

Farmington Hills, United States

Head office

Loading Map...

Operations

All Locations

Farmington Hills, US

Products and/or services of Ocuphire Pharma Inc

Nyxol: Late-stage investigational eye drop for reversing mydriasis, presbyopia, and night vision disturbances, aimed at improving visual acuity and reducing pupil size.
APX3330: An oral drug candidate targeting diabetic retinopathy and diabetic macular edema, focusing on inflammation and abnormal blood vessel growth in the retina.
MIRA-2: A clinical trial evaluating Nyxol in pediatric patients for improving night vision disturbances, with a focus on efficacy and safety.
ORION-1: A phase 2 trial assessing APX3330, targeting multiple pathways implicated in retinal inflammation and vascular disorders.
Nyxol in RM: Researching Nyxol's potential for reducing reversal of mydriasis, offering patients convenience for routine eye exams and procedures.
APX2009 & APX2014: Next-generation molecules being developed for additional ophthalmic indications, enhancing therapeutic options for retinal diseases.